Pancreatic cancer action network - Join us
Clinical Trial
Finder
Retrieving Trials
Retrieving Trials...

Back to Trial Search

Pilot Study of Neoadjuvant Modified FOLFIRINOX or Gemcitabine-nab Paclitaxel Followed by Stereotactic Body Radiotherapy (SBRT) for Patients With Locally Advanced Pancreatic Cancer and Borderline Pancreatic Inoperable Cancers

Summary

The purpose of this pilot study is to evaluate neoadjuvant therapy followed by stereotactic body radiotherapy (SBRT) for patients with borderline resectable and unresectable pancreas cancers.

General Information

NCT#: NCT03641183
Study ID: IRB00339168
Trial Phase: Pilot

Trial Sponsor: University of Alabama
Therapies Used in This Trial: Nab-paclitaxel, Fluorouracil, Gemcitabine, Oxaliplatin, Stereotactic body radiotherapy (SBRT), Irinotecan, Leucovorin, FOLFIRINOX

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account?

Request an Account


  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account.
  • In order to view this information, you need to be signed in as a Health Care Provider.
  • In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
  • This information is restricted to validated Health Care Providers.

Eligibility



-------------------------------------------------------------------------------------------

  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
  • ------------------------------------------------------------------------------------------------------
  • In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information


Back to Trial Search